Year: 2023

TORONTO, ON – December 29, 2023 – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for its 6.5 million outstanding and unlisted share purchase warrants having … Continued

TORONTO, ON – December 12, 2023 – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company“), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “Warrant Extension”), and amending the exercise price (the “Exercise Price Amendment”) of the … Continued

– Completed successful PK/PD study for otenaproxesul’s new formulation – Phase II initiation on track for upcoming quarter – Ended quarter with $28 million in cash and equivalents TORONTO, CANADA — (November 13, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies … Continued

– Study delivers data required for Phase II trial, on track to initiate next quarter – Confirms linear, dose-proportional pharmacokinetics – Complements strong safety data already reported TORONTO, CANADA — (November 9, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting … Continued

– All treatments well tolerated with no adverse safety signals – No elevations in liver enzymes TORONTO, CANADA — (November 1, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the completion of the … Continued

– Data in November will inform Phase II trial expected to launch next quarter TORONTO, CANADA — (October 18, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study … Continued

TORONTO, CANADA — (September 28, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October,  … Continued

TORONTO, CANADA — (September 8, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. … Continued

– Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study – PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 –  Ended quarter with $34.3 million in cash and equivalents TORONTO, CANADA — (August 14, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen … Continued

– Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway – PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 –  Ended year with $38.9 million in cash and equivalents TORONTO, CANADA — (June 29, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its … Continued

TORONTO, CANADA — (April 25, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s … Continued

TORONTO, CANADA — (April 18, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023. Scott Curtis, Antibe’s … Continued

TORONTO, CANADA — (April 11, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation Further to Antibe’s update of February 15, 2023, the … Continued

– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management – Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months – Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (February 15, … Continued